Heat Biologics Inc (HTBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Heat Biologics Inc (HTBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH135574D
  • |
  • Pages: 53
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Heat Biologics Inc (Heat Biologics) is a biopharmaceutical company which develops novel immuno therapeutics for the treatment of cancer. Its pipeline encompasses viagenpumatucel-L based investigational candidate targeted at the treatment of non-small cell lung cancer, and co-stimulatory antibodies targeted at hematologic malignancies, and other tumors. The co-stimulatory antibodies harness human body's natural antigen specific immune response to reprogram the immune system to offer durable clinical outcomes. Heat Biologics' off-the-shelf therapies are based on its proprietary T-cell activating platform (TCAP), which turns immunologically cold tumors hot. It has subsidiaries in the US, Germany, and Australia. Heat Biologics is headquartered in Durham, North Carolina, the US.

Heat Biologics Inc (HTBX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Heat Biologics Raises USD0.5 Million in Venture Funding 12

Heat Biologics Raises USD5 Million In Venture Financing 13

Partnerships 14

Selexis and Pelican Therapeutics Enter into Agreement 14

Heat Biologics Enters into Agreement with Adaptive Biotechnologies 15

Licensing Agreements 16

University of Miami Enters into Licensing Agreement with Heat Biologics 16

Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18

Heat Biologics Enters into Licensing Agreement with Columbia University 19

Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20

Heat Biologics Enters into Licensing Agreement with University of Miami 21

Equity Offering 22

Heat Biologics Files Registration Statement for Public Offering of Shares 22

Heat Biologics to Raise up to USD15 Million in Public Offering of Shares and Warrants 23

Heat Biologics Plans to Raise up to USD1.3 Million in Public Offering of Shares 24

Heat Biologics to Raise up to USD3.7 Million in Public Offering of Shares 25

Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26

Heat Biologics Raises USD4 Million in Public Offering of Common Stock 27

Heat Biologics Raises USD7 Million in Public Offering of Shares 28

Heat Biologics Raises USD12.3 Million in Public Offering of Shares 30

Heat Biologics Completes Underwriters' Partial Exercise Of Over-Allotment Option For IPO Of Shares For USD27 Million 32

Acquisition 34

Heat Biologics Acquires 80% Stake in Pelican Therapeutics 34

Heat Biologics Inc-Key Competitors 35

Heat Biologics Inc-Key Employees 36

Heat Biologics Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

May 15, 2018: Heat Biologics Reports First Quarter 2018 Results and Provides Corporate Update 38

Feb 28, 2018: Heat Biologics Reports Fiscal Year 2017 Financial Results 39

Nov 13, 2017: Heat Biologics Reports Third-quarter 2017 Results and Corporate Update 40

May 11, 2017: Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017 41

Mar 31, 2017: Heat Biologics Reports Fiscal Year 2016 Financial Results 43

Corporate Communications 45

Feb 28, 2018: Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards 45

Oct 23, 2017: Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards 46

Jul 03, 2017: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics 47

Jan 04, 2017: Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer 48

Product News 49

10/30/2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives Second Tranche of its USD15.2 Million CPRIT Grant Award 49

06/28/2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of USD15.2 Million CPRIT Grant Award 50

03/16/2017: Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine 51

Clinical Trials 52

Nov 11, 2017: Heat Biologics Presents Follow-up Data on its ComPACT(TM) T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53

List of Figures

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Heat Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Heat Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Heat Biologics Raises USD0.5 Million in Venture Funding 12

Heat Biologics Raises USD5 Million In Venture Financing 13

Selexis and Pelican Therapeutics Enter into Agreement 14

Heat Biologics Enters into Agreement with Adaptive Biotechnologies 15

University of Miami Enters into Licensing Agreement with Heat Biologics 16

Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18

Heat Biologics Enters into Licensing Agreement with Columbia University 19

Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20

Heat Biologics Enters into Licensing Agreement with University of Miami 21

Heat Biologics Files Registration Statement for Public Offering of Shares 22

Heat Biologics to Raise up to USD15 Million in Public Offering of Shares and Warrants 23

Heat Biologics Plans to Raise up to USD1.3 Million in Public Offering of Shares 24

Heat Biologics to Raise up to USD3.7 Million in Public Offering of Shares 25

Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26

Heat Biologics Raises USD4 Million in Public Offering of Common Stock 27

Heat Biologics Raises USD7 Million in Public Offering of Shares 28

Heat Biologics Raises USD12.3 Million in Public Offering of Shares 30

Heat Biologics Completes Underwriters' Partial Exercise Of Over-Allotment Option For IPO Of Shares For USD27 Million 32

Heat Biologics Acquires 80% Stake in Pelican Therapeutics 34

Heat Biologics Inc, Key Competitors 35

Heat Biologics Inc, Key Employees 36

Heat Biologics Inc, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Heat Biologics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 17970
Site License
USD 500 INR 35940
Corporate User License
USD 750 INR 53910

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com